Eyeing clinical proof-of-concept for HER3 drug, Amgen-partnered biotech scores $125M for precision antibodies

Eyeing clinical proof-of-concept for HER3 drug, Amgen-partnered biotech scores $125M for precision antibodies

Hummingbird discusses our HER3 program and how we are tackling the challenges of therapeutics development.